Biacore - BCOR | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Biacore - BCOR

An SI Board Since February 2000

Posts	SubjectMarks	Bans	Symbol
7	2	0	BCOR

Emcee: JEFF CHAPMAN	Type: Unmoderated

Introduction Market Data Compact

BCOR, manufactures and markets analytical instruments that employ affinity-based biosensor technology used for monitoring biomolecular interactions as they occur and provide real-time information that describes the association and dissociation of biomolecules. For the six months ended 6/30/99, revenues rose 4% to SEK142.7 million. Net income fell 5% to SEK19.6 million. Revenues benefited from strong sales in Japan. Net income was offset by currency differences.

Book Value (mrq) $4.57
Earnings (ttm) $0.46
Earnings (mrq) $0.10
Sales (ttm) $3.47
Cash (mrq) $2.82

Q4 Highlights:

* Full-year sales increased by 18% to SEK 340 million after a very strong
fourth quarter.

* Earnings per share up 29% to SEK 5.26 (4.07).

* Major victory for Biacore in U.S. patent dispute.

* Strategic focus on drug discovery as a major growth opportunity. Key
collaboration agreements signed.

* Technology breakthrough opens new application areas.

* For the full-year 2000, a sales growth in the range of 10-15% is
expected.

Market cap under $200 million currently, key deal with MLNM in December:

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today announced that it has entered into a collaborative agreement with Biacore International AB (Nasdaq: BCOR - news) under which Millennium will evaluate Biacore's latest instrumentation in drug-discovery applications. Biacore's new prototype instrument further enhances the affinity-based biosensor technology underlying all of its products, which enables detection of biomolecules and binding events in real time, without the use of labels. Millennium will utilize the improved biosensor technology to accelerate its identification of potential drug targets and of small molecules that interact with them.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
7	Make that 204,000. 184,000 were traded in Stockholm. You can check BCOR before	notyet	-	3/8/2000
6	Isn't it scary to see this stock move up 5 on only 20,000 shares! It did lo	JEFF CHAPMAN	-	3/8/2000
5	Jeff don't feel too bad. I've owned svgi for something like 2 years an	jsabelko	-	2/23/2000
4	Sure, and yes, unfortunately, I still own UTEK :)... Given the runup of semi eq	JEFF CHAPMAN	-	2/23/2000
3	Jeff, I just wanted to thank you for starting this thread. BCOR seems to have	jsabelko	-	2/22/2000
2	No doubt about that. The thing I like about BCOR and HYSQ for that matter is th	JEFF CHAPMAN	-	2/21/2000
1	This stock has profits and actual growth. If it IPOed today it would fetch a ma	notyet	-	2/20/2000

Go to reply# or date (mm/dd/yy):